Shenzhen, Guangdong Province, China & San Ramon, California, USA – April 26, 2017
HealthTell and iCarbonX today announced that they have agreed to launch collaborative ImmunoSignature research and commercial service offerings in China, Singapore, and Taiwan. As members of the Digital Life Alliance, the Companies are committed to realizing the synergistic combination of biological measurements, patient-generated data, and artificial intelligence to maintain well-being and improve healthcare outcomes. HealthTell’s ImmunoSignature Technology is an important component of iCarbonX ecosystem, providing critical immunomics information via high-throughput assays that are broadly scalable.
“The Chinese wellness and personalized medicine markets are growing rapidly, and our expanding partnership with iCarbonX provides appreciable and unique exposure to that growth,” said Dr. Bill Coslton, HealthTell’s CEO. “iCarbonX is a global innovator, driving complementary technologies together in an unprecedented way. We are excited about working with iCarbonX to expand the applications of our ImmunoSignature™ Technology, as we expand global commercialization of the platform.”
HealthTell’s ImmunoSignature Technology takes advantage of the Company’s proprietary approach to making diverse chemical libraries by leveraging standard silicon-based electronic manufacturing techniques to produce high density peptide arrays. The patterns observed when antibodies from blood samples are bound to HealthTell’s high-density peptide arrays are categorical ImmunoSignatures™ that have been validated as an indicator of the immune system’s historical and real-time physiologic response.
“HealthTell is a differentiated innovator in the Digital Life Alliance. The Company’s platform enables us to offer unique immune system profiling that is an important part of the health-related big data platform we are building at iCarbonX. We look forward to introducing our markets to the ImmunoSignature Technology this year,” said Dr. Wang Jun, CEO and Founder of iCarbonX. Under this agreement HealthTell will install the ImmunoSignature™ assay system in iCarbonX’ Shenzhen laboratory in the third quarter.
Founded in October 2015, iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
The management team has deep experience in omics technology, mobile health, medical service, biological data analysis, artificial intelligence and data mining, etc. Based on a growing digital life network, together with the world's leading partners, we plan to interpret and study your digital life to provide personalized products and services for a healthier and better life.
Founded in 2012, HealthTell is committed to empowering the next generation of medical tests and treatments for cancer, neurological diseases, autoimmune disorders, and infectious diseases. We form strategic partnerships with diagnostic and therapeutic companies and allow them access to our proprietary ImmunoSignature platform. As the first and only platform capable of broadly characterizing antibody response, we work with these partners to uncover new biological insights that can be used to dramatically improve healthcare. For more information, please visit: http://www.healthtell.com/